Aliases & Classifications for Common Wart

MalaCards integrated aliases for Common Wart:

Name: Common Wart 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11165
ICD10 33 B07 B07.8
ICD9CM 35 078.1
NCIt 50 C27087 C5028
UMLS 73 C0043037

Summaries for Common Wart

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection has symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary : Common Wart is related to haemophilus influenzae and aspergillosis, and has symptoms including raised wart An important gene associated with Common Wart is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Tuberculosis. The drugs Salicylic acid and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin and skin, and related phenotypes are hematopoietic system and immune system

Related Diseases for Common Wart

Graphical network of the top 20 diseases related to Common Wart:



Diseases related to Common Wart

Symptoms & Phenotypes for Common Wart

Symptoms:

12
  • raised wart

MGI Mouse Phenotypes related to Common Wart:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD40 CD80 CLEC4E CLEC6A CLEC7A LGALS3
2 immune system MP:0005387 9.17 CD40 CD80 CLEC4E CLEC6A CLEC7A LGALS3

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 69-72-7 338
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
3
Cantharidin Approved, Investigational Phase 4,Phase 2,Not Applicable 56-25-7
4
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
5
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6
6
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
7
Fluorouracil Approved Phase 4 51-21-8 3385
8
Epicatechin Investigational Phase 4,Phase 1 490-46-0 72276
9 Salicylates Phase 4,Phase 2,Phase 3
10 pyruvate Phase 4,Phase 2,Phase 3
11 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
12 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
13 Keratolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Analgesics Phase 4,Phase 2,Phase 3
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
16 Antirheumatic Agents Phase 4,Phase 2,Phase 3
17 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
18 Antifungal Agents Phase 4,Phase 2,Phase 3
19 Dermatologic Agents Phase 4,Phase 2,Phase 3,Not Applicable
20 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
21 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Liver Extracts Phase 4,Phase 3
24 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunoglobulins Phase 4,Phase 3,Phase 1
26 Antibodies Phase 4,Phase 3,Phase 1
27 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Tea Phase 4,Phase 3,Phase 2,Phase 1
33 Cyclosporins Phase 4
34 Calcineurin Inhibitors Phase 4
35 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1
36 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
37 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
38 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
39 Antimetabolites Phase 4,Phase 1,Phase 2
40 Insulin, Globin Zinc Phase 4,Phase 3
41 insulin Phase 4,Phase 3
42 Antibiotics, Antitubercular Phase 4
43 Anti-Bacterial Agents Phase 4
44
Ethanol Approved Phase 2, Phase 3,Phase 3,Not Applicable 64-17-5 702
45
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
46
Aminolevulinic acid Approved Phase 3 106-60-5 137
47
Furosemide Approved, Vet_approved Phase 3,Phase 2 54-31-9 3440
48
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
49
Pancrelipase Approved, Investigational Phase 3 53608-75-6
50
Benzocaine Approved, Investigational Phase 3,Not Applicable 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 208)
# Name Status NCT ID Phase Drugs
1 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4 17% Salicylate with ethyl pyruvate;Salicylates
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
4 Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
5 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4 Imiquimod 5% cream
6 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
7 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study Completed NCT02622568 Phase 4 Veregen only
8 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
9 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
10 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
11 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
12 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
13 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
14 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
15 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
16 Comparison of Five Treatments in Patients With Plantar Warts Terminated NCT01059110 Phase 4 Salicylate ointment;Imiquimod;5-Fluoro-Uracil;Cryotherapy
17 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
18 Efficacy of Laser Versus Cryotherapy in the Treatment of Warts Unknown status NCT01808443 Phase 3
19 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
20 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT03259620 Phase 3 CLS006;CLS006 Vehicle
21 A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT02971891 Phase 3 CLS006 (Furosemide) Topical Gel;Vehicle Topical Gel
22 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
23 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
24 Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01783353 Phase 2, Phase 3
25 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
26 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
27 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
28 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
29 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
30 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
31 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
32 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
33 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
34 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
35 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
36 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
37 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
38 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
39 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
40 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
41 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
42 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
43 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
44 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
45 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
46 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
47 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT01412944 Phase 3 secukinumab 150mg;secukinumab 10mg/kg i.v. regimen
48 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Completed NCT01952015 Phase 3
49 Study of A-101 Topical Solution for the Treatment of Common Warts Recruiting NCT03687372 Phase 3 A-101
50 A Study of A-101 Topical Solution for the Treatment of Common Warts Recruiting NCT03691831 Phase 3 A-101

Search NIH Clinical Center for Common Wart

Genetic Tests for Common Wart

Anatomical Context for Common Wart

The Foundational Model of Anatomy Ontology organs/tissues related to Common Wart:

19
Skin

MalaCards organs/tissues related to Common Wart:

41
Skin

Publications for Common Wart

Articles related to Common Wart:

(show all 21)
# Title Authors Year
1
Hyperkeratotic acral melanoma mimicking a common wart. ( 25973355 )
2015
2
Keratotic horn on left fifth fingertip: congenital ectopic nail misdiagnosed as a common wart. ( 22277059 )
2013
3
Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. ( 23135096 )
2012
4
Treatment options for the common wart. ( 18210913 )
2007
5
Plantar verrucous carcinoma (epithelloma cuniculatum): rare form of the common wart. ( 17214114 )
2006
6
Is duct tape occlusion therapy as effective as cryotherapy for the treatment of the common wart? ( 12361441 )
2002
7
The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). ( 12361440 )
2002
8
Human papillomavirus associated Bowen's disease of the foot: unique clinical features mimicking a common wart. ( 11525958 )
2001
9
Efficacious treatment of the common wart (verruca vulgaris). ( 1462533 )
1992
10
Common wart causing longitudinal groove in nail. ( 28150682 )
1986
11
Transformation of the common wart into squamous cell carcinoma in a patient with primary lymphedema. ( 7248909 )
1981
12
Stump the experts. A common wart. ( 7338585 )
1981
13
An unusual transformation of a common wart in a child. ( 6269499 )
1981
14
The common wart: intralesional treatment with bleomycin sulfate. ( 6159138 )
1980
15
Treatment of the common wart by induced allergic inflammation. ( 7389963 )
1980
16
Treatment of the common wart with a virus vaccine. ( 14477428 )
1962
17
Morphological characterization of the virus of the human common wart (verruca vulgaris). ( 13785470 )
1961
18
Aralen and plaquenil in treatment of the common wart. ( 13726985 )
1961
19
Common wart conjunctivitis. ( 13196997 )
1954
20
Treatment of the common wart by x-ray therapy. ( 13164671 )
1954
21
Contact x-ray therapy of the common wart. ( 14914174 )
1952

Variations for Common Wart

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Pathways for Common Wart

GO Terms for Common Wart

Cellular components related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.13 CD209 CD40 CD80
2 cell surface GO:0009986 8.92 CD209 CD40 CD80 LGALS3

Biological processes related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.54 CD40 CD80 CXCL8
2 positive regulation of T cell proliferation GO:0042102 9.43 CD209 CD80
3 positive regulation of cytokine secretion GO:0050715 9.4 CLEC4E CLEC6A
4 innate immune response GO:0045087 9.35 CD209 CLEC4E CLEC6A CLEC7A LGALS3
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 CD209 CLEC4E CLEC6A
6 defense response to protozoan GO:0042832 9.32 CD40 CLEC7A
7 regulation of T cell proliferation GO:0042129 9.26 CD209 LGALS3
8 immune system process GO:0002376 9.1 CD209 CD40 CLEC4E CLEC6A CLEC7A LGALS3

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.02 CD209 CLEC4E CLEC6A CLEC7A LGALS3
2 mannose binding GO:0005537 8.96 CD209 CLEC6A

Sources for Common Wart

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....